Despite the high P/S ratio, shareholders are holding onto Penumbra's stocks due to its strong future revenue prospects. The strong revenue forecasts are expected to keep the share price buoyant unless the analysts have significantly misjudged the company's potential.
A new generation of highly effective weight-loss and diabetes drugs known as GLP-1s has led Wall Street to spell doom for companies that have profited from obesity problem. However, the reaction on Wall Street has been extreme, creating opportunities for cooler heads, some analysts and investors say. To be sure, drugs such as$Novo-Nordisk A/S (NVO.US)$'s Ozempic and Wegovy, and Eli Lilly's Mounjaro have p...
Penumbra's earnings outlook could be brighter than reflected in the statutory profit due to one-off items. The company's profitability this year shows a good sign after previous losses.
Penumbra's low ROE and declining net income over five years hint at sub-par performance. The earnings' decline, despite profit retention, could imply a struggling business or high payout ratio. Analyst estimates, however, foresee a better earnings growth rate.
These are the top stocks as ranked by a growth model that scores companies based on a 50/50 weighting of their most recent quarterly year-on-year (YOY) percentage revenue growth and their most recent quarterly YOY earnings per share (EPS) growth. Both sales and earnings are critical factors in the success of a company. Therefore, ranking companies by only one growth metric makes a ranking susceptible to the accounting anomalies of that quarter (such as changes in tax law or...
Penumbra Stock Forum
To be sure, drugs such as $Novo-Nordisk A/S (NVO.US)$'s Ozempic and Wegovy, and Eli Lilly's Mounjaro have p...
Gap Ups
1. $Vertiv Holdings (VRT.US)$ - up 18.6%
2. $Erie Indemnity (ERIE.US)$ - up 8.7%
3. $Aspen Technology (AZPN.US)$ - up 6.5%
4. $Penske Automotive (PAG.US)$ - up 5.1%
5. $Humana (HUM.US)$ - up 3.7%
6. $Teva Pharmaceutical Industries (TEVA.US)$ - up 3.7%
7. $Encompass Health (EHC.US)$ - up 3.0%
8. $Emerson Electric (EMR.US)$ - up 2.8...
Both sales and earnings are critical factors in the success of a company. Therefore, ranking companies by only one growth metric makes a ranking susceptible to the accounting anomalies of that quarter (such as changes in tax law or...
• $Avantor (AVTR.US)$ : Citigroup Upgrades to Buy from Neutral - PT $28
• $Church & Dwight (CHD.US)$ : Deutsche Bank Upgrades to Buy from Hold - PT $85 (from $90)
• $ConocoPhillips (COP.US)$ : Erste Group Upgrades to Buy from Hold
• $Ford Motor (F.US)$ : Morgan Stanley Upgrades to Overweight from Equal Weight - PT $14
• $Silicon Motion Technology (SIMO.US)$ : Susquehanna Upgrades to Positive from Neutral - PT $108
• $Walmart (WMT.US)$ ...
• $BorgWarner (BWA.US)$ : Deutsche Bank Upgrades to Buy from Hold - PT $48 (from $43)
• $Expensify (EXFY.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $25 (from $20)
• $Grab Holdings (GRAB.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $3
• $Houlihan Lokey (HLI.US)$ : Morgan Stanley Upgrades to Equalweight from Underweight - PT $82 (from $95)
• $JPMorgan (JPM.US)$ : Berenberg Upgrades to Hold from Sell - PT ...
• $TechnipFMC (FTI.US)$ : Societe Generale Upgrades to uy from Hold - PT $10
• $Lululemon Athletica (LULU.US)$ : Truist Securities Upgrades to Buy from Hold - PT $495 (from $390)
• $NorthWestern (NWE.US)$ : Barclays Upgrades to Equal Weight From Underweight - PT $62 (from $57)
• $Portland General Electric (POR.US)$ : Barclays Upgrades to EqualWeight From Underweight - PT $57 (from $53)
• $Pricesmart (PSMT.US)$ : Scotiabank Upgrades to Sector Outperform Fro...
No comment yet